Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study-Reference-Cited by-同舟云学术

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study

Published:2012-11-09 Issue:11 Volume:7 Page:e49289
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Hocqueloux Laurent,Choisy Philippe,Le Moal Gwenaël,Borsa-Lebas Françoise,Plainchamp David,Legac Eric,Prazuck Thierry,de la Tribonnière Xavier,Yazdanpanah Yazdan,Parienti Jean-Jacques

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference25 articles.

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1–166. (n.d.). Available: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 2 April 2011.

2. Yeni P (2010) Prise en charge médicale des personnes infectées par le VIH. Paris: La documentation française.

3. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen;J Ghosn;Antivir Ther (Lond),2010

5. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients;MA Valantin;J Antimicrob Chemother,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study;Journal of Clinical Epidemiology;2020-02

2. Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France;Open Forum Infectious Diseases;2019-03-01

3. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study;Journal of Microbiology, Immunology and Infection;2017-12

4. The ASSURE study: HIV ‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir;HIV Medicine;2015-07-14

5. Four days a week or less on appropriate anti‐HIV drug combinations provided long‐term optimal maintenance in 94 patients: the ICCARRE project;The FASEB Journal;2015-04